The Role and Potential of
18F-FDG
BRAF mutation
PET/CT
artificial intelligence
malignant melanoma
precision medicine
radiomics
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
08 Apr 2022
08 Apr 2022
Historique:
received:
20
03
2022
revised:
06
04
2022
accepted:
07
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Novel therapeutic approaches, consisting of immune check-point inhibitors (ICIs) and molecularly targeted therapy, have thoroughly changed the clinical management of malignant melanoma (MM), the most frequent and deadly skin cancer. Since only 30-40% of MM patients respond to ICIs, imaging biomarkers suitable for the pre-therapeutic stratification and response assessment are warmly welcome. In this scenario, positron emission computed tomography (PET/CT) with
Identifiants
pubmed: 35453977
pii: diagnostics12040929
doi: 10.3390/diagnostics12040929
pmc: PMC9028862
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Nucl Med. 2017 Feb;58(2):282-287
pubmed: 27660141
Cancer Biother Radiopharm. 2022 Apr;37(3):226-232
pubmed: 35128935
J Natl Cancer Inst. 2011 Jan 19;103(2):129-42
pubmed: 21081714
Ann Oncol. 2022 Jan;33(1):99-106
pubmed: 34687894
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96
pubmed: 25359635
AJR Am J Roentgenol. 2019 Apr 1;:1-9
pubmed: 30933647
Melanoma Res. 2010 Dec;20(6):511-6
pubmed: 20890225
Int J Mol Sci. 2019 May 30;20(11):
pubmed: 31151303
Insights Imaging. 2020 Aug 12;11(1):91
pubmed: 32785796
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2298-2310
pubmed: 31346755
Q J Nucl Med Mol Imaging. 2009 Feb;53(1):17-22
pubmed: 18665122
Nat Med. 2004 Sep;10(9):909-15
pubmed: 15340416
Clin Nucl Med. 2020 Mar;45(3):187-194
pubmed: 31977479
J Nucl Med. 2019 Nov;60(11):1545-1552
pubmed: 31481581
EJC Suppl. 2013 Sep;11(2):81-91
pubmed: 26217116
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2787-2795
pubmed: 32296882
Invest New Drugs. 2018 Aug;36(4):638-646
pubmed: 29159766
Cancers (Basel). 2021 May 26;13(11):
pubmed: 34073477
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Melanoma Res. 2020 Aug;30(4):358-363
pubmed: 32628431
Cancer Imaging. 2022 Feb 5;22(1):11
pubmed: 35123578
PLoS One. 2018 Mar 29;13(3):e0193946
pubmed: 29596475
J Nucl Med. 2009 Aug;50(8):1385; author reply 1385
pubmed: 19617329
Melanoma Manag. 2018 Jun 28;5(1):MMT06
pubmed: 30190932
J Nucl Med. 2019 Mar;60(3):335-341
pubmed: 30413661
Oncogene. 2014 May 8;33(19):2413-22
pubmed: 23728340
Semin Nucl Med. 2021 Mar;51(2):126-133
pubmed: 33509369
Int J Cancer. 2022 Jun 1;150(11):1870-1878
pubmed: 35001363
EJNMMI Res. 2019 Jan 29;9(1):8
pubmed: 30694399
Syst Rev. 2012 Dec 13;1:62
pubmed: 23237499
Cancer Immunol Immunother. 2018 Aug;67(8):1261-1270
pubmed: 29872898
Hum Pathol. 1984 Dec;15(12):1147-65
pubmed: 6500548
Artif Cells Nanomed Biotechnol. 2018;46(sup1):1080-1087
pubmed: 29482360
Oncotarget. 2017 Jan 31;8(5):8069-8082
pubmed: 28039443
Eur Radiol. 2022 May;32(5):3398-3407
pubmed: 34779873
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Nucl Med Commun. 2016 Feb;37(2):122-8
pubmed: 26440571
Middle East Afr J Ophthalmol. 2018 Apr-Jun;25(2):91-95
pubmed: 30122854
Cancer Imaging. 2020 Jul 6;20(1):44
pubmed: 32631431
Cancers (Basel). 2019 Aug 31;11(9):
pubmed: 31480470
Cancers (Basel). 2020 Jul 07;12(7):
pubmed: 32645969
Clin Nucl Med. 2003 Dec;28(12):961-5
pubmed: 14663316
Eur J Cancer. 2013 Jan;49(2):395-402
pubmed: 22981500
Tumori. 2005 Mar-Apr;91(2):173-6
pubmed: 15948547
BMC Cancer. 2016 Jul 07;16:413
pubmed: 27389173
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383
pubmed: 29124281
Cancer Cell. 2011 Jan 18;19(1):11-5
pubmed: 21251612
Eur J Nucl Med Mol Imaging. 2011 May;38(5):822-31
pubmed: 21210112
Front Oncol. 2021 Dec 09;11:741612
pubmed: 34956868
Lancet Reg Health Eur. 2021 Jan 06;2:100024
pubmed: 34557790
Korean J Radiol. 2022 Jan;23(1):112-123
pubmed: 34983098
Melanoma Res. 2019 Apr;29(2):178-186
pubmed: 30653029
Nucl Med Commun. 2020 Jan;41(1):78-86
pubmed: 31800510
Cancer Med. 2020 Mar;9(5):1603-1612
pubmed: 31951322
Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1592-8
pubmed: 22801730
Nature. 1987 Jul 16-22;328(6127):267-70
pubmed: 3496540
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2776-2786
pubmed: 32338306
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Diagnostics (Basel). 2022 Feb 02;12(2):
pubmed: 35204479
Ann Surg Oncol. 2018 Oct;25(11):3326-3333
pubmed: 30105436
Curr Alzheimer Res. 2017;14(2):198-207
pubmed: 27334942
Crit Rev Oncol Hematol. 2020 Sep;153:103044
pubmed: 32673997
Future Oncol. 2021 Feb;17(6):689-699
pubmed: 33084375
Med Sci (Basel). 2021 Oct 20;9(4):
pubmed: 34698235
Trials. 2019 Feb 4;20(1):99
pubmed: 30717811
Radiology. 2020 Oct;297(1):87-96
pubmed: 32749204
J Clin Oncol. 2012 May 10;30(14):1628-34
pubmed: 22454415
Am J Cancer Res. 2020 Apr 01;10(4):1103-1114
pubmed: 32368388
Phys Med. 2014 May;30(3):340-5
pubmed: 24239343
Nucl Med Commun. 2010 Sep;31(9):766-72
pubmed: 20585271
Clin Nucl Med. 2019 Apr;44(4):e272-e279
pubmed: 30688730
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
Diagnostics (Basel). 2020 Sep 15;10(9):
pubmed: 32942729
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2309-2311
pubmed: 33420612